Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » Cepheid Receives CE Mark for SARS-CoV-2, Flu A/B, RSV Combination Test

Cepheid Receives CE Mark for SARS-CoV-2, Flu A/B, RSV Combination Test

Nov 24, 2020
|
staff reporter

NEW YORK ─ Sunnyvale, California-based Cepheid on Tuesday announced it has obtained CE-IVD marking for its Xpert Xpress SARS-CoV-2/Flu/RSV rapid molecular diagnostic test to detect from a single patient sample the viruses that cause COVID-19, Flu A, Flu B, and RSV infections.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Italy Seeks to Manufacture Vaccines

Italy has held talks with vaccine developers to manufacture mRNA-based SARS-CoV-2 vaccines, according to the Financial Times.

Fetal Tissue Research Restrictions Reversed

The Associated Press reports US officials are removing restrictions on fetal tissue research that were added during the Trump Administration.

Funds for Viral Genomic Surveillance

The Biden Administration is investing $1.7 billion to detect and monitor SARS-CoV-2 variants.

PLOS Papers on Aicardi-Goutières Syndrome, COVID-19 in Colombian Amazon, Cancer MicroRNAs

In PLOS this week: genome instability in Aicardi-Goutières Syndrome, introduction of SARS-CoV-2 to the Colombian Amazon, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. LGC Biosearch Technologies Gets FDA Emergency Use Authorization for SARS-CoV-2 Test

  2. Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

  3. Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.